RAJAF TFA Therapeutics, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1885680 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-0.6%
TTM net income YoY31.6%
TTM EPS YoY—
Revenue 3-yr CAGR185.9%
Net income 3-yr CAGR—
Margins
Gross margin61.1%
Operating margin-11.3%
Net margin-12.4%
FCF margin—
EBITDA margin-0.5%
Returns
ROE—
ROA-3.3%
ROIC (approx.)—
Asset turnover0.27x
Leverage & solvency
Liabilities / assets111.5%
Debt / equity—
Current ratio0.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.23x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2023Q4*2023-12-31 | 2022Q4*2022-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $315,502 | — |
| Cost of revenue | $30,842 | — |
| Gross profit | $284,660 | — |
| SG&A expense | $350,152 | $317,681 |
| Operating income | $117,999 | -$264,482 |
| Interest expense | $22,007 | $71,772 |
| Pretax income | $91,930 | -$36,891 |
| Net income | $973,422 | -$77,046 |
| EBITDA | $173,716 | -$107,828 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $23,104 | $6,628 |
| Receivables | — | $149,510 |
| Inventory | — | $313,530 |
| Current assets | $327,175 | $501,552 |
| PP&E, net | $2.81M | $75,510 |
| Total assets | $3.35M | $2.10M |
| Current liabilities | $2.97M | $2.52M |
| Short-term debt | — | $57,109 |
| Long-term debt | $431,079 | $414,000 |
| Total debt | $431,079 | $471,109 |
| Total liabilities | $3.50M | $3.06M |
| Shareholders' equity | -$151,796 | -$951,334 |
| Net debt | $407,975 | $464,481 |
| Shares outstanding | 111.12M | 111.12M |
| Cash flow statement | ||
| Operating cash flow | -$1.23M | -$110,817 |
| Capital expenditure | -$1.33M | — |
| Free cash flow | $101,453 | — |
| Investing cash flow | $1.22M | -$1,456 |
| Financing cash flow | $48,030 | $6,970 |
| Depreciation & amortization | $55,717 | $156,654 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.